Preparation and in vivo safety evaluations of antileukemic homoharringtonine-loaded PEGylated liposomes.

Related Articles

Preparation and in vivo safety evaluations of antileukemic homoharringtonine-loaded PEGylated liposomes.

Drug Dev Ind Pharm. 2017 Apr;43(4):652-660

Authors: Liu D, Xing J, Xiong F, Yang F, Gu N

Abstract
In order to improve the in vivo safety and specific delivery efficiency of the antileukemic homoharringtonine (HHT) at the targets, the long-circulating PEGylated liposomes loaded with HHT (LCLipo-HHT) were prepared. Their physical characteristics, in vitro drug release, in vivo pharmacokinetic properties and elementary toxicity were evaluated. The mean diameter of the prepared LCLipo-HHT is 75.6 ± 3.2 nm and the zeta potential is -16.9 ± 2.5 mV. The entrapment efficiency of HHT in the liposomes is 69.5 ± 1.7%. In pharmacokinetic experiments, an increased plasma concentration as well as blood circulation time was obtained when distearoyl phosphoethanolamine-PEG 2000 lipid was added in the formulation, which results in enhancing drug delivery efficiency. Hemolysis test, vascular irritation test and acute toxicity test were used to demonstrate toxicity of LCLipo-HHT. Compared with clinical HHT injection dosage, LCLipo-HHT indicated no vascular irritation, good hemocompatibility, as well as much better safety. Therefore, the prepared LCLipo-HHT can be used as a promising anticancer formulation for antileukemic therapy in the future.

PMID: 28005445 [PubMed - indexed for MEDLINE]

http://ift.tt/2hzFbcq